Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer
IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Ashley F. Hall, JD, to the position of Chief Development Officer. In this role, Ms. Hall will oversee nonclinical and clinical operations, global regulatory affairs, pharmaceutical development, and program management for all the company’s development programs.
“We are happy to welcome Ashley to the Reneo leadership team,” said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals. “Ashley is an experienced leader in the biopharmaceutical industry, with a track record of successfully bringing multiple novel drug products to market in the U.S., Europe, and other regions of the world. Her deep understanding of the drug development process will be instrumental in the development of REN001.”
“I am very excited to be joining the extraordinary team at Reneo,” said Ms. Hall. “REN001 has the potential to benefit patients suffering from a range of diseases driven by mitochondrial dysfunction. I look forward to working with the Reneo team to advance this important product through the next series of critical milestones.”
Ms. Hall brings more than 20 years of experience in global drug development to Reneo. Prior to joining Reneo, Ms. Hall was the Chief Development Officer and Head of Global Regulatory Affairs at Esperion Therapeutics, where she successfully led the regulatory approvals of the company’s two lead cholesterol lowering products, Nexletol® and Nexlizet®, in major markets around the world. Prior to joining Esperion, Ms. Hall was the Global Regulatory Lead at Amgen, overseeing the regulatory strategy and global filings for the Repatha® program, which led to the world’s first approval of a PCSK9 inhibitor for cholesterol lowering. Prior to Esperion, Ms. Hall was the Vice President of Regulatory Affairs at Micromet (acquired by Amgen) where she led the Blincyto® rare disease oncology program. Ms. Hall also held prior leadership roles at RevoGenex, MedImmune (acquired by AstraZeneca), and Abraxis BioScience.
Ms. Hall earned a Juris Doctorate (JD) from the University of San Diego School of Law and a Bachelor of Science in biochemistry and cell biology, with a minor in philosophy (bioethics), from the University of California, San Diego.
In connection with Ms. Hall’s employment with the company, Ms. Hall will be granted inducement awards consisting of an option to purchase 180,000 shares of common stock, plus a restricted stock unit award covering 30,000 shares of common stock. The Compensation Committee of Reneo’s Board of Directors approved the awards as inducements material to Ms. Hall’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).
About Reneo Pharmaceuticals
Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria.
About REN001
REN001 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for three rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disorder type V (McArdle disease). For more information on REN001 clinical trials, please see clinicaltrials.gov.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the advancement of REN001 development programs. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will,” “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Reneo’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Reneo’s business in general, and the other risks described in Reneo’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contacts:
Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Vinny Jindal
Chief Financial Officer
Reneo Pharmaceuticals, Inc.
investors@reneopharma.com
